InvestSMART

Imricor Medical Systems Inc (ASX:IMR)

ALERT: Price-sensitive ASX Announcement for IMR
Current share price for IMR : $1.970 0.07 (3.68%)+
Announcement
Release
10 Aug 2026 8:38AM
Price at Release
$1.900
Full Release
download
Summary
In Q2 CY2026, Imricor Medical Systems, Inc. announced its U.S. commercial launch with Rady Children’s Hospital–San Diego as its first customer, aiming to establish a radiation-free cardiac catheterisation program. The company launched a new business vertical, Imricor Cardiovascular, targeting over 2,250 U.S. hospitals. It received FDA clearance for pediatric label expansions for key products and submitted significant regulatory filings for additional approvals. Financially, Imricor noted a quarterly revenue of US$60.5k and a net loss of US$7.4m, with ongoing cash outflows and a bolstered balance sheet post a A$60m placement. The company is focused on completing key clinical trials and expanding its U.S. team to support its scale-up efforts.
Key Points
  • U.S. commercial launch commenced with Rady Children’s Hospital–San Diego as the first customer for NorthStar®.
  • Launch of Imricor Cardiovascular, targeting over 2,250 U.S. hospitals for MR-guided cardiac procedures.
  • FDA cleared pediatric label expansions for NorthStar and Vision-MR® Diagnostic Catheter.
  • Third PMA module submitted for Vision-MR Ablation Catheter, with the final module pending trial completion.
  • Q2 CY2026 revenue was US$60.5k with a net loss of US$7.4m.
  • Operating cash outflow of approximately US$6.1m for the quarter.
  • Secured A$60m placement to reinforce financial standing ahead of U.S. expansion.
  • Imricor Finance launched to facilitate hospital purchases through vendor financing.
  • VISABL-AFL pivotal trial nearing completion triggering final PMA module submission.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.